Business Context and Reporting Period
This Form 8-K is filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on November 15, 2023. The report addresses a 1-for-25 reverse stock split and a reduction in authorized shares that became effective on September 8, 2023. The filing serves to update historical financial data in the Company's 2022 Form 10-K to reflect these capital structure changes.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that it does not contain new financial results or updates to the Company's financial condition other than the recasting of share counts and per-share data to reflect the reverse stock split.
Material Changes
- Reverse Stock Split: A 1-for-25 reverse stock split of common stock was effected.
- Authorized Shares Reduction: The total number of authorized shares was reduced from 500,000,000 to 20,000,000.
- Historical Recasting: Exhibits 99.1 and 99.2 provide recast versions of the 2022 Form 10-K's Management's Discussion and Analysis and Financial Statements to align with the new share structure.
Guidance, Outlook, and Risks
The filing contains no new management guidance, outlook, or discussion of risks and contingencies. It clarifies that the report does not reflect events occurring after the original filing of the 2022 Form 10-K, other than the capital structure adjustments described.
Investor Verification Checklist
- Verify the updated share count and per-share financial metrics in the recast 2022 Form 10-K (Exhibits 99.1 and 99.2).
- Confirm the effective date of the reverse stock split (September 8, 2023) for historical trading data analysis.
- Note that this filing is a technical update for share structure and does not indicate new operational developments or financial performance changes.